Selank is a synthetic tuftsin analog that users often mainly take off‑label for anxiety reduction and stress relief, with a smaller group also pursuing cognitive enhancement and focus. Most community reports describe a commonly daily intranasal dose around 500 µg, often on a five‑days‑on/two‑days‑off cycle, while clinician guidance typically recommends 250–750 µg daily intranasal without a set cycling pattern. The honest tradeoff is that the supporting evidence is thin relative to the volume of discussion, with most exploratory uses lacking posted results.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Selank’s evidence is low, resting on four published treatment studies and one published diagnostic/mechanistic study in humans. The two human indications consist of four treatment studies and one diagnostic/mechanistic study, while the third indication is animal‑only preclinical research; across all three—plus a noted single‑trial long‑tail—there are no registered trials, no completed trials, and no blinded results posted. This absence of trial‑level data means the human signal remains limited to preliminary, single‑trial observations without replication.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
4 studies
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 26 out-of-stock offers not shown
How Selank is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The four cited human studies do not report a consistent dose, frequency, or cycling regimen for Selank, so no reliable dosage can be extracted from this tier.
Clinicians typically administer Selank via the intranasal route at a dose of 300 mcg once daily, with reported doses ranging from 250 mcg to 750 mcg per day.
Most community users dose Selank at around 500 mcg, though many did not specify a schedule; among those who did, daily dosing was typical, with a smaller group using twice daily. About five users reported cycling five days on and two days off, while the majority used it continuously.